Our ‘FeNO by NIOX®’ range helps physicians around the world see airway inflammation clearly, helping improve asthma diagnosis and management.
Location: United Kingdom, England, Oxford
Total raised: $46.82M
Investors 3
| Date | Name | Website |
| - | Entreprene... | entreprene... |
| - | Gilde Heal... | gildehealt... |
| - | GIMV | gimv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 24.05.2012 | Series B | $26.81M | - |
| 07.07.2011 | - | $18.2M | - |
| - | Grant | $1.81M | - |
Mentions in press and media 3
| Date | Title | Description |
| 24.05.2012 | Prosonix Raised £17.1M in Series B Equity Financing | Prosonix, a Oxford, UK-based specialty pharma company developing novel respiratory medicines, has held the second closing of a £17.1m Series B equity financing round. Backers include Gimv, which invested £5.7m, Ventech, Gilde Healthcare Par... |
| 07.07.2011 | Prosonix Receives £11.4M Equity Investment | Prosonix Ltd., an Oxford, UK-based developer of high value respiratory therapies enabled by its novel and proprietary particle engineering technology, has received an £11.4m equity investment. Investors include Gilde Healthcare Partners, ne... |
| - | Prosonix Receives £1.3M Grant Award from the Biomedical Catalyst to Accelerate Development of Multi-component Particle™ (MCP™) based Combination Respiratory Medicines | The award will support a research consortium led by Prosonix that includes internationally recognised respiratory disease and drug inhalation experts at three of the UK’s premier academic institutions: Professor Peter Barnes and Dr Omar Usm... |